- In October 2024, Calviri (a biotech specialized in canine cancer vaccines) initiated a clinical trial for its immunotherapy vaccine targeting early-stage hemangiosarcoma in dogs. This SOCH study evaluates whether combining the vaccine with surgery and chemotherapy can significantly extend survival compared to standard care
- In March 2025, ELIAS Animal Health received full USDA approval for its ELIAS Cancer Immunotherapy (ECI)—the first licensed autologous cell therapy for treating canine osteosarcoma—opening access via apheresis treatment centers across the U.S.
- In August 2024, FidoCure (One Health Company) secured a U.S. patent for its AI-enhanced targeted therapy and biomarker platform for canine bladder cancer, representing a major step forward in personalized veterinary oncology
- In January 2025, Vetigenics, a biotech focused on canine monoclonal antibodies, closed a USD 6 million seed round. They achieved positive results from a clinical trial of an anti-CTLA4 therapy for canine oral melanoma and are nearing completion of an anti-PD1 study for urothelial carcinoma
